Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMW-029
- Development stage
- Unknown
- Lead developer
- Immunowake
- Modality
- Antibody-Based Therapeutics
01
Overview
IMW-029 is an investigational antibody drug developed by Immunowake for the treatment of neoplasms (cancers). It is currently in early clinical development, with its highest reported phase being Phase 1. The specific mechanism of action and molecular target have not been publicly disclosed as of the latest available information. The drug represents a novel approach from Immunowake, a company focused on innovative therapies for patients who do not respond to traditional immunotherapy methods[1][3].
- Other names
- IMW-029IMW029IMW 029
Beyond the preview
Go deeper on IMW-029.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMW-029.